Literature DB >> 15196265

Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cells.

C M Radder1, H Beekhuizen, H H H Kanhai, A Brand.   

Abstract

Maternal anti-HPA-1a antibodies can cause severe fetal and neonatal alloimmune thrombocytopenia (FNAIT), complicated by intracranial haemorrhage (ICH). Antenatal treatment with maternal intravenous immunoglobulin (IVIG) seems to protect against ICH even when thrombocytopenia persists. The aim of this study was to investigate if anti-HPA-1a antibodies and IVIG potentially affect vascular endothelial cells (ECs) in order to identify susceptibility for ICH. Human umbilical cord endothelial cells (HUVEC) were incubated with anti-HPA-1a antibodies with or without polyclonal IVIG and evaluated for EC activation. Maternal sera with anti-HPA-1a antibodies affected neither the EC expression of intracellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1) and tissue factor (TF) nor the release of van Willebrand factor (vWF) or interleukin (IL)-8 nor the integrity of ECs. Maternal sera obtained after IVIG treatment and polyclonal IVIG decrease constitutive and cytokine-induced ICAM-1 and VCAM-1 expression on ECs. The results show that maternal anti-HPA-1a antibodies cause no activation or damage of ECs in this model. The clinical relevance of the de-activating properties of IVIG on EC activation with respect to ICH deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196265      PMCID: PMC1809094          DOI: 10.1111/j.1365-2249.2004.02496.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  52 in total

1.  Cultured human endothelial cells synthesize a plasma membrane protein complex immunologically related to the platelet glycoprotein IIb/IIIa complex.

Authors:  O C Leeksma; J Zandbergen-Spaargaren; J C Giltay; J A van Mourik
Journal:  Blood       Date:  1986-04       Impact factor: 22.113

2.  Bacterial species- and strain-dependent induction of tissue factor in human vascular endothelial cells.

Authors:  M H Veltrop; H Beekhuizen; J Thompson
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  CNS lesions in neonatal isoimmune thrombocytopenia.

Authors:  S Naidu; H Messmore; V Caserta; M Fine
Journal:  Arch Neurol       Date:  1983-09

4.  Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens.

Authors:  P Parham; C J Barnstable; W F Bodmer
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

5.  A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia.

Authors:  C M Radder; A Brand; H H Kanhai
Journal:  Am J Obstet Gynecol       Date:  2001-09       Impact factor: 8.661

Review 6.  Fetomaternal alloimmune thrombocytopenia.

Authors:  R Ahya; M L Turner; S J Urbaniak
Journal:  Transfus Apher Sci       Date:  2001-10       Impact factor: 1.764

7.  Normal human IgG prevents endothelial cell activation induced by TNFalpha and oxidized low-density lipoprotein atherogenic stimuli.

Authors:  N Ronda; F Bernini; R Giacosa; R Gatti; N Baldini; C Buzio; G Orlandini
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

8.  [Neonatal alloimmune thrombopenia. Clinical and biological study of 84 cases].

Authors:  J Y Muller; M F Reznikoff-Etievant; C Patereau; C Dangu; N Chesnel
Journal:  Presse Med       Date:  1985-01-19       Impact factor: 1.228

9.  The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening.

Authors:  L M Williamson; G Hackett; J Rennie; C R Palmer; C Maciver; R Hadfield; D Hughes; S Jobson; W H Ouwehand
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

10.  Immune complexes in thrombocytopenic patients: cause or effect?

Authors:  R J Trent; R L Clancy; V Danis; A Basten
Journal:  Br J Haematol       Date:  1980-04       Impact factor: 6.998

View more
  6 in total

1.  Postnatal management of fetal and neonatal alloimmune thrombocytopenia: the role of matched platelet transfusion and IVIG.

Authors:  Arjan B te Pas; Enrico Lopriore; Eline S A van den Akker; Dick Oepkes; Humphrey H Kanhai; Anneke Brand; Frans J Walther
Journal:  Eur J Pediatr       Date:  2006-12-20       Impact factor: 3.183

2.  Neonatal outcome in alloimmune thrombocytopenia after maternal treatment with intravenous immunoglobulin.

Authors:  N Margreth Van Der Lugt; Marije M Kamphuis; Noortje P M Paridaans; Anouk Figee; Dick Oepkes; Frans J Walther; Enrico Lopriore
Journal:  Blood Transfus       Date:  2014-06-19       Impact factor: 3.443

3.  Antiendothelial αvβ3 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune Thrombocytopenia.

Authors:  Sentot Santoso; Hevi Wihadmadyatami; Tamam Bakchoul; Silke Werth; Nadia Al-Fakhri; Gregor Bein; Volker Kiefel; Jieqing Zhu; Peter J Newman; Behnaz Bayat; Ulrich J Sachs
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-06-09       Impact factor: 8.311

4.  Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia.

Authors:  Cedric Ghevaert; David A Wilcox; Juan Fang; Kathryn L Armour; Mike R Clark; Willem H Ouwehand; Lorna M Williamson
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

5.  Th17 cells reflect colon submucosal pathologic changes in active eosinophilic granulomatosis with polyangiitis.

Authors:  Naomi Tsurikisawa; Chiyako Oshikata; Takahiro Tsuburai; Satoshi Sugano; Yoko Nakamura; Takuya Shimoda; Shunpei Tamama; Ken Adachi; Ayako Horita; Ikuo Saito; Hiroshi Saito
Journal:  BMC Immunol       Date:  2015-12-29       Impact factor: 3.615

Review 6.  High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.

Authors:  Xiaosheng Liu; Wei Cao; Taisheng Li
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.